Melline G M Schilham1, Roderick C N van den Bergh1, Daan J Reesink2, Erik J R J van der Hoeven3, Ivo G Schoots4,5, Harm H E van Melick1. 1. Department of Urology, St. Antonius Hospital Utrecht/Nieuwegein, Koekoekslaan 1, Utrecht, 3435CM, The Netherlands. 2. Department of Urology, St. Antonius Hospital Utrecht/Nieuwegein, Koekoekslaan 1, Utrecht, 3435CM, The Netherlands. d.reesink@antoniusziekenhuis.nl. 3. Department of Radiology, St. Antonius Hospital Utrecht/Nieuwegein, Utrecht, The Netherlands. 4. Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. 5. Department of Radiology and Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Abstract
PURPOSE: In biopsy naïve men suspected for prostate cancer (PCa), it is uncertain how a risk-calculator and bi-parametric (bp) MRI should be combined to decide on prostate biopsy, balancing cancer detection rates and diagnostic burden. METHODS: Prospective, single centre cohort study (August 2018-April 2019). All patients referred with serum PSA ≥ 3 ng/ml or abnormal digital rectal examination received bpMRI and risk for PCa was calculated using the ERSPC risk-calculator. Men with either PI-RADS ≥ 3 or calculator risk-score > 20% were recommended to undergo systematic biopsy (SB) and targeted biopsy (TB) of any visible lesion (reference pathway). Eight different derived diagnostic pathways were compared to the reference pathway regarding cancer detection, number of biopsies and bpMRIs performed. RESULTS: Of 496 patients; 233 (47%) had a risk-calculator score of > 20%; 201 (41%) had PI-RADS score ≥ 3. The reference pathway detected PCa in 32.1%, clinically significant (cs) PCa in 19.4%, with 41% avoided biopsies, but 0% avoided bpMRI. Stratification with only risk-calculator: 76% csPCa diagnosed, 53% avoided biopsies and 100% avoided bpMRI. Stratification with only bpMRI: 97% csPCa diagnosed, 59% avoided biopsies, but 0% avoided bpMRI. A pathway with risk-calculator first, followed only with bpMRI when high-risk: 81% csPCa diagnosed, 72% avoided biopsies and 53% avoided bpMRI. CONCLUSION: Upfront bpMRI as a risk stratification tool outperforms risk-calculator in detecting significant disease. Applying the risk-calculator first to decide on performing an MRI, avoids 1 out of 2 MRIs, but up to 1 out of 5 significant cancers are missed.
PURPOSE: In biopsy naïve men suspected for prostate cancer (PCa), it is uncertain how a risk-calculator and bi-parametric (bp) MRI should be combined to decide on prostate biopsy, balancing cancer detection rates and diagnostic burden. METHODS: Prospective, single centre cohort study (August 2018-April 2019). All patients referred with serum PSA ≥ 3 ng/ml or abnormal digital rectal examination received bpMRI and risk for PCa was calculated using the ERSPC risk-calculator. Men with either PI-RADS ≥ 3 or calculator risk-score > 20% were recommended to undergo systematic biopsy (SB) and targeted biopsy (TB) of any visible lesion (reference pathway). Eight different derived diagnostic pathways were compared to the reference pathway regarding cancer detection, number of biopsies and bpMRIs performed. RESULTS: Of 496 patients; 233 (47%) had a risk-calculator score of > 20%; 201 (41%) had PI-RADS score ≥ 3. The reference pathway detected PCa in 32.1%, clinically significant (cs) PCa in 19.4%, with 41% avoided biopsies, but 0% avoided bpMRI. Stratification with only risk-calculator: 76% csPCa diagnosed, 53% avoided biopsies and 100% avoided bpMRI. Stratification with only bpMRI: 97% csPCa diagnosed, 59% avoided biopsies, but 0% avoided bpMRI. A pathway with risk-calculator first, followed only with bpMRI when high-risk: 81% csPCa diagnosed, 72% avoided biopsies and 53% avoided bpMRI. CONCLUSION: Upfront bpMRI as a risk stratification tool outperforms risk-calculator in detecting significant disease. Applying the risk-calculator first to decide on performing an MRI, avoids 1 out of 2 MRIs, but up to 1 out of 5 significant cancers are missed.
Authors: Paul C Moldovan; Thomas Van den Broeck; Richard Sylvester; Lorenzo Marconi; Joaquim Bellmunt; Roderick C N van den Bergh; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Theo H van der Kwast; Vsevolod B Matveev; Henk G van der Poel; Maria De Santis; Ivo G Schoots; Thomas Wiegel; Cathy Yuhong Yuan; Philip Cornford; Nicolas Mottet; Thomas B Lam; Olivier Rouvière Journal: Eur Urol Date: 2017-03-21 Impact factor: 20.096
Authors: Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Maria De Santis; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Vsevolod B Matveev; Paul C Moldovan; Roderick C N van den Bergh; Thomas Van den Broeck; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Ivo G Schoots; Thomas Wiegel; Philip Cornford Journal: Eur Urol Date: 2016-08-25 Impact factor: 20.096
Authors: Monique J Roobol; Ewout W Steyerberg; Ries Kranse; Tineke Wolters; Roderick C N van den Bergh; Chris H Bangma; Fritz H Schröder Journal: Eur Urol Date: 2009-09-01 Impact factor: 20.096
Authors: Timur H Kuru; Matthias C Roethke; Philip Rieker; Wilfried Roth; Michael Fenchel; Markus Hohenfellner; Heinz-Peter Schlemmer; Boris A Hadaschik Journal: BJU Int Date: 2013-08-13 Impact factor: 5.588
Authors: Jonathan I Epstein; Mahul B Amin; Himisha Beltran; Tamara L Lotan; Juan-Miguel Mosquera; Victor E Reuter; Brian D Robinson; Patricia Troncoso; Mark A Rubin Journal: Am J Surg Pathol Date: 2014-06 Impact factor: 6.394
Authors: Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton Journal: Lancet Date: 2017-01-20 Impact factor: 79.321
Authors: Veeru Kasivisvanathan; Antti S Rannikko; Marcelo Borghi; Valeria Panebianco; Lance A Mynderse; Markku H Vaarala; Alberto Briganti; Lars Budäus; Giles Hellawell; Richard G Hindley; Monique J Roobol; Scott Eggener; Maneesh Ghei; Arnauld Villers; Franck Bladou; Geert M Villeirs; Jaspal Virdi; Silvan Boxler; Grégoire Robert; Paras B Singh; Wulphert Venderink; Boris A Hadaschik; Alain Ruffion; Jim C Hu; Daniel Margolis; Sébastien Crouzet; Laurence Klotz; Samir S Taneja; Peter Pinto; Inderbir Gill; Clare Allen; Francesco Giganti; Alex Freeman; Stephen Morris; Shonit Punwani; Norman R Williams; Chris Brew-Graves; Jonathan Deeks; Yemisi Takwoingi; Mark Emberton; Caroline M Moore Journal: N Engl J Med Date: 2018-03-18 Impact factor: 176.079
Authors: Marinus J Hagens; Piter J Stelwagen; Hans Veerman; Sybren P Rynja; Martijn Smeenge; Vincent van der Noort; Ton A Roeleveld; Jolien van Kesteren; Sebastiaan Remmers; Monique J Roobol; Pim J van Leeuwen; Henk G van der Poel Journal: World J Urol Date: 2022-10-16 Impact factor: 3.661